Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX 75246, USA.
EMD Serono, Inc., Rockland, MA 02370, USA; an affiliate of Merck KGaA, Darmstadt, Germany.
Future Oncol. 2021 Jun;17(18):2339-2350. doi: 10.2217/fon-2020-1250. Epub 2021 Mar 12.
To assess clinical outcomes in patients with locally advanced (la) or metastatic (m) Merkel cell carcinoma (MCC) initiating first-line (1L) avelumab in a USA community oncology setting. Adults with laMCC or mMCC initiating 1L avelumab were identified from The US Oncology Network electronic health record database and chart review. Median overall survival and progression-free survival were not reached in laMCC (n = 9) vs 20.2 and 10.0 months in mMCC (n = 19); response rates were similar (66.7% vs 63.2%). This is the first study to show clinical benefit in patients with laMCC receiving 1L avelumab in a US real-world setting. Response rates in patients with mMCC were consistent with pivotal trials.
评估美国社区肿瘤学环境中初治局部晚期（la）或转移性（m） Merkel 细胞癌（MCC）患者的临床结局，这些患者起始一线（1L）avelumab 治疗。从美国肿瘤学网络电子健康记录数据库和图表审查中确定了初治 1Lavelumab 的 laMCC 或 mMCC 成年患者。laMCC（n=9）的中位总生存期和无进展生存期未达到，而 mMCC（n=19）分别为 20.2 和 10.0 个月；缓解率相似（66.7% vs 63.2%）。这是第一项在真实世界环境中接受 1Lavelumab 治疗的 laMCC 患者显示临床获益的研究。mMCC 患者的缓解率与关键性试验一致。
